Personalized medicine: Taubman Scholar Dr. Arul Chinnaiyan weighs in on cancer treatment potential
Dr. Arul Chinnaiyan, director of the Michigan Center for Translational Pathology and a Taubman Scholar, was quoted on Feb. 16 in a Detroit News article about the prospects for personalized cancer treatment:
(Dr. Chinnaiyan) is working to develop new molecular tests and therapeutics for human diseases, with a focus on cancer.
Not all patients respond to conventional treatments, so when they reach advanced stages of cancer they are enrolled in a clinical sequencing program.
Since 2011, U-M has sequenced 150 adult patients and 15 children, Chinnaiyan said. The six-week process sequences the cancer tumor along with normal tissue and compares them.
"We're trying to figure out what mutations have occurred in the patient's tumor relative to the normal genome," Chinnaiyan said. "We analyze the data in the context of the mutation to see if there are any clinical trials that might be appropriate or approved drugs that might work."
A small percentage of patients fit the criteria for clinical trials or approved drugs, and an even smaller percentage will respond. But early research has offered some success stories that will be published in academic journals in the near future.
"Patients who have failed conventional therapies are looking for options," Chinnaiyan said.
Click here to read the complete article.
Taubman-sponsored research offers breast tumor insights
Taubman Emerging Scholar Dr. Scott Tomlins has authored a new study about phyllodes tumors.
New U-M President visits Taubman Institute
The Institute hosted a fellow clinician-scientist when the University of Michigan’s new president paid a visit to the A. Alfred Taubman Biomedical Science Research Building.
Familial ALS affects generations
Detroit News column featuring Dr. Eva Feldman depicts the toll of the disease on one Metro Detroit family
news & events
In the News
PBS series features institute director on Jan. 18
"The Embrace of Aging," a documentary series airing Sundays at 2:30 p.m. on Detroit Public Televsion, features Taubman Institute Director Eva Feldman, M.D., Ph.D. and her landmark ALS stem cell trial in the Jan. 18 episode.
Drug cuts risk of bone-marrow transplant side effect
Taubman Emerging Scholar Sung Won Choi, M.D., is the lead author of a new study that finds a new way to help prevent graft-vs-host disease in cancer patients receiving bone-marrow transplants.
Study: Two types of cancer stem cells lead to metastasis
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to a new study published by Taubman Senior Scholar Dr. Max Wicha.